share_log

Modular Medical Announces Licensing and Partnership Agreement With Nudge BG

Modular Medical Announces Licensing and Partnership Agreement With Nudge BG

模塊醫療宣佈與Nudge BG達成許可和合作協議
Accesswire ·  12/20 05:01

-Modular Medical will collaborate with Nudge BG to bring to market an adaptive full closed loop Automated Insulin Delivery system that does not require mealtime announcements

-Modular Medical將與Nudge BG合作推出一種適應性全閉環自動胰島素輸送系統,該系統無需用餐時的通知

-Effort will be led be Nudge BG founder and noted AID expert, Lane Desborough

-這項工作將由Nudge BG創始人和著名AID專家Lane Desborough領導

SAN DIEGO, CA / ACCESSWIRE / December 19, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to meet the needs of "almost-pumpers" with its user-friendly and affordable design, announced a licensing and partnership agreement with Nudge BG.

加利福尼亞州聖地亞哥 / ACCESSWIRE / 2024年12月19日 / Modular Medical, Inc. (納斯達克:MODD) ("Modular Medical"或"公司"),是一家胰島素輸送科技公司,擁有首個FDA批准的專爲 "幾乎需要注射胰島素的患者 "設計的貼片泵,其用戶友好、價格合理的設計,宣佈與Nudge BG達成許可和合作協議。

"We are very excited to partner with Modular Medical to bring the next generation of automated insulin delivery ("AID") to the marketplace," said Lane Desborough, CEO of Nudge BG. "Nudge BG's adaptive full closed loop AID technology, unlike the present Hybrid Closed Loop products, complements Modular Medical's easy-to-use and cost-effective MODD1 insulin pump technology. Our combined system is intended to nudge blood glucose by making small changes to insulin delivery based on estimated glucose inputs from a continuous glucose monitor."

Nudge BG的首席執行官Lane Desborough表示:"我們非常高興能夠與Modular Medical合作,將下一代自動胰島素輸送("AID")推向市場。"Nudge BG的適應性全閉環AID技術與當前的混合閉環產品不同,能夠補充Modular Medical易於使用和具有成本效益的MODD1胰島素泵技術。我們的聯合系統旨在通過根據來自連續血糖監測儀的估計血糖輸入,進行小幅度調整以推動血糖水平。"

"We believe most people living with insulin-requiring diabetes find it difficult or impossible to sustain the therapy effort which contemporary AID systems demand, including counting carbohydrates and calculating bolus delivery amounts, preventing them from reaping the benefits of the present technology. It has been the goal of Nudge BG to design an AID system that will truly make the diabetes management experience both effective and less burdensome for users. Our system will fully automate mealtime insulin delivery, freeing people with diabetes from the risk and difficulty of bolusing, while still achieving glycemic goals," said Desborough.

"我們相信,大多數患有胰島素依賴性糖尿病的人發現維持現代AID系統所要求的治療工作是困難或不可能的,包括計算碳水化合物和計算胰島素劑量,這使他們無法享受當前技術的好處。Nudge BG的目標是設計一個真正能使糖尿病管理體驗既有效又不那麼繁瑣的AID系統。我們的系統將完全自動化用餐時的胰島素輸送,解放糖尿病患者免於注射的風險與困難,同時仍能達到血糖目標,"Desborough說道。

Paul DiPerna, President and CTO of Modular Medical, stated "Our goal at Modular Medical is to bring the benefits of insulin pump technology to the approximately 80% of potential adopters who are not on pumps because they see current AID-enabled systems as too complex, too cumbersome, and too costly. The Nudge BG partnership is another step in our efforts to make the experience of diabetes management as low touch and simple as possible by reducing the amount of time, training, and effort a user will spend daily on managing insulin, while still providing the beneficial results of pumping as compared to multiple daily injections."

Modular Medical的總裁兼首席技術官Paul DiPerna表示:"我們在Modular Medical的目標是將胰島素泵技術的好處帶給大約80%的潛在用戶,他們尚未使用泵,因爲他們認爲現有的AID支持系統過於複雜、繁瑣和成本太高。Nudge BG的合作是我們努力使糖尿病管理體驗儘可能簡單的又一步,通過減少用戶每日管理胰島素所花費的時間、培訓和精力,同時仍提供與多次日常注射相比的泵送有益效果。"

Mr. Desborough has been developing control algorithms in safety-critical industries for the past 35 years. He was formerly Co-Founder and Chief Engineer of Bigfoot Biomedical and previously served as Chief Engineer, Closed Loop/Insulin Delivery at Medtronic Diabetes. Mr. Desborough has been developing commercial AID systems since 2010, soon after his son was diagnosed with type-1 diabetes.

德斯伯勒先生在安全關鍵行業開發控制算法已有35年。他曾是Bigfoot Biomedical的聯合創始人和首席工程師,之前在美敦力糖尿病部門擔任閉環/胰島素輸送的首席工程師。自2010年以來,德斯伯勒先生一直在開發商業化的AID系統,在他的兒子被診斷爲1型糖尿病後不久。

Forward-Looking Statements

前瞻性聲明

This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statements contained in this press release. These forward looking statements and factors include, but are not limited to, whether Modular Medical and Nudge BG can successfully bring to market an AID system, the successful integration of Nudge BG's AID technology with Modular Medical's pump products, the anticipated performance and expected benefits of the proposed Modular Medical and Nudge AID system, whether Modular Medical can successfully develop its proprietary technologies, whether the market will accept Modular Medical's products and services, the future product roadmap and development activities, anticipated consumer demand for the Modular Medical's products, whether Modular Medical can successfully manufacture its products at high volumes, general economic, and industry or political conditions in the United States or internationally, as well as other risk factors and business considerations described in Modular Medical's SEC filings, including its annual report on Form 10-K. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press release represent Modular Medical's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. Modular Medical assumes no obligation to update these forward-looking statements, except as required by law.

本新聞稿包含根據1995年《私人證券訴訟改革法》中的安全港條款所作出的前瞻性聲明。這些前瞻性聲明受到風險、趨勢和不確定性的影響,這可能導致實際結果與本新聞稿中包含的前瞻性聲明有所不同。這些前瞻性聲明和因素包括但不限於,模塊醫療和Nudge BG是否能成功推出AID系統,Nudge BG的AID技術與模塊醫療的泵產品的成功整合,預期的模塊醫療和Nudge AID系統的性能和預期收益,模塊醫療是否能夠成功開發其專有技術,市場是否會接受模塊醫療的產品和服務,未來的產品路線圖和開發活動,消費者對模塊醫療產品的預期需求,模塊醫療是否能夠成功大規模生產其產品,以及美國或國際上的一般經濟、行業或政治條件,以及在模塊醫療的SEC文件中描述的其他風險因素和業務考慮,包括其10-K表格的年度報告。本新聞稿中的任何前瞻性聲明都應在這些重要風險因素的背景下進行評估。此外,本新聞稿中包含的任何前瞻性聲明僅代表模塊醫療在其發佈日期的觀點,不應被視爲代表其在任何後續日期的觀點。模塊醫療無義務更新這些前瞻性聲明,除非法律要求。

About Modular Medical

關於醫療模塊化公司

Modular Medical, Inc. (Nasdaq:MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Our mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."

Modular Medical, Inc.(納斯達克:MODD)是一家處於開發階段的醫療器械公司,計劃推出下一代胰島素傳遞技術。利用其專利技術,公司旨在消除複雜性與有效性之間的權衡,從而使高質量的胰島素傳遞既經濟又易於學習。我們的使命是改善糖尿病患者獲取最高標準的血糖控制的機會,超越"超用戶"的範疇,爲"我們所有人提供糖尿病護理。"

Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at .

模塊醫療公司由保羅·迪佩爾納創辦,他是一位經驗豐富的醫療器械專業人士和微流體工程師。在創辦模塊醫療之前,迪佩爾納先生於2005年成立了Tandem Diabetes,併發明和設計了其t:slim胰島素泵。更多信息請訪問。

About Nudge BG

關於Nudge BG

Nudge BG is an engineering consulting services and algorithm development company focused on modeling, simulation, and control of physiological systems. Nudge BG was founded by Lane Desborough.

Nudge BG是一家工程諮詢服務和算法開發公司,專注於生理系統的建模、仿真和控制。Nudge BG由萊恩·德斯博羅創立。

All trademarks mentioned herein are the property of their respective owners.

這裏提到的所有商標均爲其各自所有者的財產。

CONTACT:
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
IR@modular-medical.com

聯繫方式:
傑布·貝瑟
首席執行官
模塊化醫療公司
+1 (617) 399-1741
IR@modular-medical.com

SOURCE: Modular Medical, Inc.

來源:Modular Medical, Inc。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論